Table 1 Comparison of patient demographics and tumor characteristics of AUS-ILC and HK-ILC cohorts
| Â | Â | No. of patients (%) | Â | ||
|---|---|---|---|---|---|
Characteristics | All ILC | AUS-ILC | HK-ILC | p | |
Age at diagnosis | Â | Â | Â | Â | |
|  | Median (range) | 55 (34 – 86) | 64 (34 – 86) | 50 (34 – 82) | <0.0005 |
| Â | <= 35 | 2 (0.9%) | 1 (1.1%) | 1 (0.7%) | Â |
| Â | 36 - 50 | 84 (36.2%) | 14 (14.9%) | 70 (49.6%) | Â |
|  | ≥ 51 | 146 (62.9%) | 79 (84.0%) | 67 (48.6%) |  |
Menopausal status | Â | Â | Â | Â | |
| Â | Pre-menopausal | 39 (30.5%) | 8 (18.2%) | 31 (36.9%) | 0.029 |
| Â | Post-menopausal | 89 (69.5%) | 36 (81.8%) | 53 (63.1%) | Â |
Tumor size (cm) | Â | Â | Â | Â | |
|  | Median (range) | 2.4 (0.18 – 20.0) | 2.4 (0.5 – 20.0) | 2.5 (0.18 – 10.1) | 0.825 |
LN involvement | Â | Â | Â | Â | |
| Â | Negative | 129 (57.3%) | 45 (52.9%) | 84 (60.0%) | 0.299 |
| Â | Positive | 96 (42.7%) | 40 (47.1%) | 56 (40.0%) | Â |
ER | Â | Â | Â | Â | Â |
| Â | Negative | 12 (5.2%) | 2 (2.2%) | 10 (7.2%) | 0.089 |
| Â | Positive | 220 (94.8%) | 91 (97.8%) | 129 (92.8%) | Â |
PR | Â | Â | Â | Â | Â |
| Â | Negative | 48 (20.9%) | 14 (15.2%) | 34 (24.6%) | 0.085 |
| Â | Positive | 182 (79.1%) | 78 (84.8%) | 104 (75.4%) | Â |
HER2 | Â | Â | Â | Â | |
| Â | Negative | 191 (94.1%) | 85 (93.4%) | 106 (94.6%) | 0.71 |
| Â | Positive | 12 (5.9%) | 6 (6.6%) | 6 (5.4%) | Â |
Ki67 (%) | Â | Â | Â | Â | |
| Â | Median | 5.0 | 5.0 | 6.0 | 0.746 |
|  | ≤ 5 | 83 (50.6%) | 17 (54.8%) | 66 (49.6%) |  |
| Â | 6 - 9 | 32 (19.5%) | 0 (0.0%) | 32 (24.1%) | Â |
|  | ≥ 10 | 49 (29.9%) | 14 (45.2%) | 35 (26.3%) |  |